Clinical Trial Update: Diabetic Ketoacidosis From New SGLT2i: Can Genomics Estimate Risk

View source ↗

Summary

A completed clinical trial investigates whether genomics can estimate the risk of diabetic ketoacidosis in people with type 2 diabetes treated with a new SGLT2 …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Ketoacidosis
• Type 2 Diabetes Mellitus

Drugs mentioned

• SGLT2 inhibitor (unspecified) (SGLT2 inhibitor)

Snippet

Sponsor: Mount Sinai Hospital, Canada | Conditions: Diabetes Type 2, DKA | Status: COMPLETED